[1] CUI C, MO XT, TU SQ, et al.Progress in clinical pharmacology of hydroxychloroquine sulfate[J]. Chinese Journal of Clinical Pharma-cology and Therapeutics(中国临床药理学与治疗学), 2020, 25(2): 221-226. [2] Expert group on clinical treatment of coronavirus diseases in Shanghai in 2019. Expert consensus on comprehensive treatment of coronavirus diseases in Shanghai in 2019 in 2019. Expert consensus on comprehensive treatment of coronavirus diseases in Shanghai in 2019[J]. Chinese Journal of Infectious Diseases(中华传染病杂志), 2020, 38(3): 134-138. [3] ZHANG SL, MIAO CY.Pharmacological characteristics of chloroquine and hydroxychloroquine and application of New Coronavirus pneumonia (COVID-19) treatment[J]. China Journal of Pharmacology and Toxicology(中国药理学与毒理学杂志), 2020, 34(4): 261-270. [4] CHRISTOPHE B, WASSIM D, NATASCHA C, et al.Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities[J]. J Med Chem, 2006, 49(9): 2845-2849. [5] WANG T, LIU JC, PANG Y.Pharmacological mechanism and safety risk analysis of hydroxychloroquine[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020,17(7): 385-388. [6] JORGE A, UNG C, YOUNG LH, et al.Hydroxychloroquine retinopathy-implications of research advances for rheumatology care[J]. Nat Rev Rheumatol, 2018, 14(12): 693-703. [7] National Center for ADR monitoring, Center for drug reevaluation of State Food and drug administration. WHO terminology of adverse drug reactions(WHO药品不良反应术语集)[M]. Beijing: China Medical Science Press, 2002: 1-172. [8] LI SS, DING YX, YIN AQ.Signal mining of 392 spontaneous reports of cefoperazone / sulbactam adverse reactions[J]. Journal of Pharmacoepidemiology(药物流行病学杂志), 2018, 27(12): 815-818. [9] KOU GX, WANG Y, GUO J, et al.Signal mining and analysis of adverse reaction events of digestive dysfunction induced by sofosbuvir[J]. Journal of Clinical Hepatobiliary Diseases(临床肝胆病杂志), 2018, 34(1): 68-72. [10] SRINIVASA A, TOSOUNIDOU S, GORDON C.Increased incidence of gastrointestinal side effects in patients taking hydroxychloroquine:a brand-related issue?[J]. J Rheumatol, 2017, 44(3): 398. [11] COSTEDOAT-CHALUMEAU N, HULOT JS, AMOURA Z, et al.Heart conduction disorders related to antimalarials toxicity:an analysis of electrocardiograms in 85 patients treated with hydroxy-chloroquine for connective tissue diseases[J]. Rheumatology, 2007, 46(5): 808-810. [12] YUSUF I, FOOT B, GALLOWAY J, et al.The Royal College of Ophthalmologists recommendations on screening for hydroxych-loroquine and chloroquine users in the United Kingdom:executive summary[J]. Eye, 2018, 32(7): 1168-1173. [13] WANG L, ZHANG N, GONG L, et al.Detection and evaluation of adverse reaction signals of chloroquine and hydroxychloroquine based on FDA adverse event database and designated medical events[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2020,40(18): 1921-1928. [14] PONTICELLI C, MORONI G.Hydroxychloroquine in systemic lupus erythematosus (SLE)[J]. Expert Opinion on Drug Saf, 2017, 16(1/6): 411-419. [15] GAO Q.Chloroquine pharmacological characteristics and recomm-endations for the treatment of New Coronavirus pneumonia[J]. China Journal of Schistosomiasis Control, 2020, 32(2): 119-122, 139. [16] NOAH F.Embracing the unknown: disentangling the complexities of the soil microbiome[J]. Nat Rev Microbiol, 2017, 15(10): 579-590. [17] SUN WJ, XU BX, LIU YQ.51 case analysis of antiviral drugs in new coronavirus pneumonia patients[J]. China Hospital Drug Evaluation and Analysis(中国医院用药评价与分析), 2021, 21(3): 362-365. [18] State Health Commission of the People's Republic of China. Novel coronavirus pneumonia for adjusting the dosage and dosage of chloroquine[EB/OL]. (2020-02-28)[2020-02-28]. http://www.nhc.gov.cn/yzygj/s7653p/202002/0293d017621941f6b2a4890035243730.shtml. |